Terms: = Prostate cancer AND FOXL2, BPES, 668, ENSG00000183770, P58012, PFRK, POF3, PINTO, BPES1 AND Prognosis
5 results:
1. Characterization of metabolism-associated molecular patterns in prostate cancer.
Yang B; Jiang Y; Yang J; Zhou W; Yang T; Zhang R; Xu J; Guo H
BMC Urol; 2023 Jun; 23(1):104. PubMed ID: 37280589
[TBL] [Abstract] [Full Text] [Related]
2. Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion >5%: a propensity score matching analysis from SEER database.
Chen J; Wang Z; Zhao J; Zhu S; Sun G; Liu J; Zhang H; Zhang X; Shen P; Shi M; Zeng H
Sci Rep; 2019 Nov; 9(1):17985. PubMed ID: 31784574
[TBL] [Abstract] [Full Text] [Related]
3. Evaluation of neutrophil-to-lymphocyte ratio as a prognostic indicator in a Singapore cohort of patients with clinically localized prostate cancer treated with prostatectomy.
Lu Y; Huang HH; Lau WKO
World J Urol; 2020 Jan; 38(1):103-109. PubMed ID: 30953141
[TBL] [Abstract] [Full Text] [Related]
4. The role of magnetic resonance image guided prostate biopsy in stratifying men for risk of extracapsular extension at radical prostatectomy. Raskolnikov D, George AK, Rais-Bahrami S, Turkbey B, Siddiqui MM, Shakir NA, Okoro C, Rothwax JT, Walton-Diaz A, Sankineni S, Su D, Stamatakis L, Merino MJ, Choyke PL, Wood BJ, pinto PA. Urologic Oncology Branch, National cancer Institute, National Institutes of Health, Bethesda, Maryland; Molecular Imaging Program, National cancer Institute, National Institutes of Health, Bethesda, Maryland; Laboratory of Pathology, National cancer Institute, National Institutes of Health, Bethesda, Maryland; Center for Interventional Oncology, National cancer Institute & Clinical Center, National Institutes of Health, Bethesda, Maryland; Urologic Oncology Branch, National cancer Institute, National Institutes of Health, Bethesda, Maryland; Center for Interventional Oncology, National cancer Institute & Clinical Center, National Institutes of Health, Bethesda, Maryland; e-mail: pintop@mail.nih.gov.J Urol. 2015 Jul;194(1):105-11. [Epub 2015 Jan 23]. doi: 10.1016/j.juro.2015.01.072.
Scott E
Urol Oncol; 2017 Mar; 35(3):121. PubMed ID: 28159491
[TBL] [Abstract] [Full Text] [Related]
5. Grading of prostatic cancer (I): An analysis of the prognostic significance of single characteristics.
Schroeder FH; Blom JH; Hop WC; Mostofi FK
Prostate; 1985; 6(1):81-100. PubMed ID: 3969374
[TBL] [Abstract] [Full Text] [Related]
